Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 345

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 345
---
-term and long-term business focus. Our current, short-term
goals relate to the Cannabis Genomic Study and the resulting development of a variety of new cannabis strains, and, over the next 5 years,
we plan to process those results in order to become an international cannabis research and product development company, with a globally-recognized
brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist,
manage & lease to universities, state governments, licensed dispensary owners and organic grow operators on a contract basis with
a concentration on the legal and medical cannabis sector.

Our long-term plan is to
become a true “Seed-to-Sale” global holding company providing infrastructure, financial solutions, product development, and
real estate options in this new emerging market. Our long term growth may also come from the acquisition of synergistic businesses, such
as distilleries, to make anything from infused beverages to super oxygenated water with CBD and THC. Currently, we have formed WEED Australia
Ltd., registered as an unlisted public company in Australia to address this Global demand. We have also formed WEED Israel Cannabis Ltd.,
an Israeli corporation, to address future global demand. We will look to conduct future research, marketing, import/exporting, and manufacturing
of our proprietary products on an international level. 

On April 20, 2017, we entered
into a Share Exchange Agreement with Sangre AT, LLC, a Wyoming limited liability company, under which we acquired all of the issued and
outstanding limited liability company membership units of Sangre in exchange for Five Hundred Thousand (500,000) shares of our common
stock, restricted in accordance with Rule 144. As a result of this agreement, Sangre is a wholly-owned subsidiary of WEED, Inc..

This discussion and analysis
should be read in conjunction with our financial statements included as part of this Annual Report.

Results of Operations for the Years Ended December
31, 2024 and 2023

    Year Ended December 31,

    2024

    2023

    Revenue
     
    $
    -

    $
    -

    Operating expenses:

    General and administrative expenses

    351,116

    394,617

    Professional fees

    156,290

    323,559

    Depreciation and amortization

    22,586

    52,392

    Total operating expenses

    529,992